Senior Research Associate / Associate Scientist, Pre-clinical Sciences

Jounce Therapeutics - Cambridge, MA

Full-time
Role / Responsibilities
We are looking for a creative and highly motivated scientist to join the Preclinical Sciences group at Jounce Therapeutics. The successful candidate will be an integral part of a team of scientists supporting the preclinical and clinical development of novel cancer Biologics. The primary responsibilities of the candidate will include the development of cell-based, mechanistic assays to support preclinical research and clinical development. The candidate will be responsible for the proper design and execution of experiments, data analysis and interpretation, thorough documentation of work, and clear communication of results both in group settings and in written reports. The candidate must be capable of working across functional groups and communicating results with scientists from diverse backgrounds. Lastly, the candidate must be a highly-motivated self-starter capable of working independently and as part of a team.

Responsibilities:
Development and execution of bioanalytical and cell-based assays to support development of novel immunotherapies from research through to clinical development stage.
Thorough documentation of experiments and communication of results across functional teams.
Drafting documents in support of regulatory filings.
Qualifications
BS in a basic science with 3+ years of relevant laboratory experience, with industrial experience a plus.
Experience and comfort with the isolation of immune cells from blood and tissue, testing therapeutics in cellular assays, and phenotyping of immune cells.
Experience and comfort with mouse tumor models (syngeneic and xenograft).
Extensive hands-on experience with immunological techniques including multi-parameter flow cytometry, single-cell sorting, immunoassays such as ELISA/MSD, in vitro cytotoxicity assays (ADCC & CDC), and reporter bioassays development.
Able to work with human and animal tissue and blood or blood products.
Proficient at independently managing scientific projects involving designing and executing experiments, analyzing data, and reporting conclusions to team members.
Excellent organizational and time management skills.
Able to thrive in a highly collaborative, fast-paced, team-oriented environment with colleagues from diverse disciplines.
Familiarity working in GxP environments is a plus.
Statement
Jounce Therapeutics is an equal opportunity employer and does not discriminate in its employment decisions on the basis of race, color, national origin, age, physical or mental disability, marital status, religion, creed, sex, or political beliefs. We offer a competitive salary and benefits package. All applicants should be legally entitled to work for any employer in the U.S.

To apply, please visit https://careers-jouncetx.icims.com/.

Company Summary
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce’s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com.